1.80 USD
▼-0.19-9.55%
盘后 2.58 0.00%
2026-09-16
市值
$46.52M
市盈率
—
EPS
-2.17
股息率
—
52 周区间
1.79 – 16.00
成交量
422.28K
Beta
1.86
目标价
16.50
52W 低 1.7952W 高 16.00
价格走势
公司简介
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targe...